ALNYLAM PHARMACEUTICALS, INC. (ALNY) Form 10-Q — Oct 29, 2026
Alnylam reported Q3 2026 total revenues of $1.458 billion, up 17% year-over-year, with net product revenues of $1.292 billion up 52% from $851.1 million, driven by the TTR…
Key figures
- Eps
- 15.72
- Revenue
- 1458086000
- Net Income
- 2167335000
- Total Debt
- approximately $1.014B convertible debt carrying value ($361.5M 2027 Notes current + $651.1M 2028 Notes long-term), plus $1.735B liabilities related to sale of future royalties and development funding
- Revenue Yoy
- 17% (Q3 2026 total revenues of $1.458B vs $1.249B in Q3 2025)
- Total Assets
- 7994672000
- Cash Position
- $1.754B cash and equivalents plus $1.833B marketable debt securities
- Shares Outstanding
- 133937576
- Q3 basic eps
- 16.19
- Q3 tax benefit
- 1871525000
- Nine month revenue
- 3916209000
- Q3 product revenue
- 1291946000
- Accumulated deficit
- $4.16B as of September 30, 2026
- Nine month net income
- 2537820000
- Q3 product revenue yoy
- 52% vs $851.1M
- Effective interest rate royalty liability
- 15%
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.